What does the merger of Jaguar and Napo mean for jaguar health?
“We are thrilled that the merger of Jaguar and Napo has become effective. It is truly transformational for Jaguar Health to forward-integrate into an important revenue stream from Mytesi®, for which we hold unencumbered global rights and are pursuing multiple follow-on indications for various chronic gastrointestinal disorders.
What happened to Napo Pharmaceuticals?
In July 2017, two companies founded by Ms. Conte—Napo Pharmaceuticals, a human-focused pharmaceuticals company, and Jaguar Animal Health, the veterinary-focused licensor of all of Napo’s technology—merged and now comprise Jaguar Health.
Who is the CEO of jaguar health?
Ms. Conte is the founder, president and chief executive officer, and a member of the board of directors, of Jaguar Health, a commercial-stage pharmaceuticals company committed to discovering, developing and commercializing plant-based prescription medicines for urgent global health needs.
What does a Jaguar scientist do?
At Jaguar, Dr. Mike supervises all animal health clinical studies, is involved in regulatory, safety assessment and manufacturing, and he advises on the many other scientific and medical activities within the company.
What is Napocares?
NapoCares is Napo Pharmaceuticals' comprehensive patient support services program , designed to make it easier for eligible patients to receive support to start and continue Mytesi ® treatment. NapoCares offers support options for patients, whether uninsured, underinsured, or insured. Services include a Copay Savings Program to help commercially insured patients save on out-of-pocket costs; a Patient Assistance Program for uninsured patients; support to help Mytesi patients understand their insurance coverage; support for prior authorizations and appeals; linkage to specialty pharmacies to fill Mytesi prescriptions; mail order pharmacy support; and a patient call center to answer any Mytesi-related questions.
What is iAssist NapoCares?
iAssist, a web-based component of the NapoCares™ patient support program, automates and streamlines the patient prescription process
Is Jaguar Health a pharmaceutical company?
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.
What is Jaguar Health?
is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.
What is napo care?
NapoCares is Napo Pharmaceuticals' comprehensive patient support services program , designed to make it easier for eligible patients to receive support to start and continue Mytesi ® treatment. NapoCares offers support options for patients, whether uninsured, underinsured, or insured. Services include a Copay Savings Program to help commercially insured patients save on out-of-pocket costs; a Patient Assistance Program for uninsured patients; support to help Mytesi patients understand their insurance coverage; support for prior authorizations and appeals; linkage to specialty pharmacies to fill Mytesi prescriptions; mail order pharmacy support; and a patient call center to answer any Mytesi-related questions.
Lisa Conte: Founder & CEO
Ms. Conte is the founder, president and chief executive officer, and a member of the board of directors, of Jaguar Health, a commercial-stage pharmaceuticals company committed to discovering, developing and commercializing plant-based prescription medicines for urgent global health needs.
Carol Lizak: Chief Financial Officer
Ms. Lizak has 20+ years of corporate controllership and financial planning & analysis experience under U.S. GAAP & IFRS. Prior to joining Jaguar, she served as senior director and corporate controller of Zosano Pharma Corporation, as controller of Quantum Secure, Inc., and as executive director, corporate controller of Alexza Pharmaceuticals, Inc.
Steven King, PhD: Chief Sustainable Supply, Ethnobotanical Research & IP Officer
Dr. King has served as our head of sustainable supply, ethnobotanical research and intellectual property since 2004. Prior to that, Dr. King served as the Vice President of Ethnobotany and Conservation at Shaman Pharmaceuticals, Inc. Dr.
Darlene Horton, M.D.: Chief Medical Officer, Napo Pharmaceuticals
Dr. Horton brings 25 years of clinical research and development, medical affairs, senior executive, and consulting experience in the development of investigational and commercialized biopharmaceutical and drug-device combination products.
David Sesin, PhD: Chief Manufacturing Officer
David is a pharmaceutical scientist with more than 30 years of experience ranging from drug discovery through manufacturing. He is the developer of the crofelemer manufacturing process.
Jonathan Wolin, JD, MBA, CPA: Chief of Staff, Chief Compliance Officer & General Counsel
Mr. Wolin joined Jaguar’s team in November 2018. He brings more than 25 years of compliance, legal, and business experience with a number of life science, biotech and healthcare companies. Prior to joining Jaguar, Mr. Wolin was the Chief Administrative Officer for Pacific Pulmonary Services.
Ian H. Wendt, MBA: Chief Commercial Officer
Prior to joining Jaguar, Mr. Wendt was at Gilead Sciences in a variety of field leadership and marketing roles in the HIV and hepatitis C therapeutic areas.